Cancer need to become a National Priority in China

A new research indicated that the treatment with poly (ADP-ribose) polymerase (PARP) inhibitors, together with chemotherapy drugs, could be applied for RUNX leukemia. This study was published in Cell journal Reports.

Unlike other cancer is more common in the elderly, leukemia has a high incidence among young people. In recent years, the breakthrough treatment of the leukemia is few. According to the previous study, RUNX1 is one of the most frequent mutations of genes in leukemia. And RUNX3 is associated with the development of the disease.

The result showed that ablation of both Runx1 and Runx3 led to defective DNA repair. Recent technological advances have shown frequent deletions of chromosome 21q, including the RUNX1 locus, in patients with congenital syndromic thrombocytopenia with leukemia predisposition.

It is clearly demonstrated that human leukemia cell lines expressing the RUNX1-ETO fusion gene are sensitive to MMC, at least partially in a fusion gene-dependent manner. This sensitivity was further enhanced in the presence of PARP inhibitor. The treatment with PARP inhibitors, together with DNA ICL and/or standard chemotherapy drugs, could be applied for RUNX leukemia. Because deregulation in RUNX family genes is now found in a wide spectrum of cancers, this combined therapy can potentially be extended to common cancers.

PARP is found in the cell’s nucleus. The main role is to detect and signal single-strand DNA breaks (SSB) to the enzymatic machinery involved in the SSB repair. In this study, PARP play the imported role in the treatment of the leukemia, and it is the breakthrough treatment of the leukemia.

Recently, Chinese hospitals are struggling hard to accommodate the increasing numbers of patients, especially the patients have cancer. Ten years ago, surgeons here removed tumours once or twice daily. Now they perform at least ten operations every day. The cancer hospital recently doubled their size but is still struggling to cope with demand. "No matter where you go in this hospital, you will never find an empty bed." Cancer rates may be falling in many developed countries in western world but they are steadily rising in China every year.

Cancer is now the leading cause of death in China but the health ministry seems ill-equipped to deal with the problem. China has approximately 20% of the world's population, but it has 22% of new cancer cases and 27% of the world's cancer deaths. Statistics on cancer cases nationwide are hard to find as China does not maintain a national database. There are no obvious national campaigns to educate citizens on the avoidable causes of cancer, like smoking. The country's National Cancer Centre, which was supposed to open in 2012, doesn't even have a website. Reliable cancer statistics are also hard to find. In 2008, the Chinese Academy of Medical Science launched the China Cancer Registration Project, with 219 registration spots across China documenting cancer data. However, it has yielded little new information. The project's last report was released in 2013, using data from 2010. To date, China lacks a single database tracking national cancer rates. Cancer screening programs are virtually non-existent. The country's fragile healthcare system also means that many aren't diagnosed until it is too late.

Numerologist Warda is hooked on OG-L002 fishing, collecting. And lastly her encouragement comes from socializing along with her companions.